NCT07492680 2026-03-25
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Bristol-Myers Squibb
Phase 2 Not yet recruiting
Bristol-Myers Squibb
Washington University School of Medicine
NYU Langone Health
Second Affiliated Hospital, School of Medicine, Zhejiang University
NRG Oncology
Tianjin Medical University Cancer Institute and Hospital
Jonsson Comprehensive Cancer Center
University of California, San Francisco
ZSky Biotech Inc
Everfront Biotech Co., Ltd.